Table 1.
Clinicopathologic characteristics of 52 patients with relapsed or refractory acute myeloid leukemia treated with CLAM
| Characteristics | Value |
|---|---|
| Gender | |
| Male | 26 |
| Female | 26 |
| Age | |
| 18‐45 y | 24 |
| 46‐65 y | 28 |
| Median age, y (range) | 46 (22‐65) |
| Characteristics at diagnosis | |
| Median leucocyte count, ×109/L (range) | 11.4 (0.59‐377) |
| Median hemoglobin, g/dL (range) | 8.1 (3.9‐12.3) |
| Median platelet count, ×109/L (range) | 70 (8‐433) |
| Median marrow blast percentage (range) | 68.5 (20‐96) |
| Karyotype | |
| Normal | 25 |
| Abnormal | 27 |
| t(8;21)(q22;q22.1); RUNX1‐RUNX1T1 | 7 |
| inv(16)(p13.1q22)/t(16;16)(p13.1;q22); CBFB‐MYH11 | 2 |
| t(9;11)(p21.2;q23.3); MLLT3‐KMT2A | 1 |
| inv(3)(q21.3q26.2)/t(3;3)(q21.2;q23.3); GATA2‐MECOM(EVI1) | 6 |
| t(v;11q23.3)/ del(11)(q23); KMT2A rearranged | 2 |
| Complexa | 2 |
| Others | 7 |
| Characteristics at the start of CLAM | |
| Nonremission after first induction | 21 |
| First relapse | 31 |
| Median time to first relapse, mo (range) | 12 (2‐53) |
| >12 mo from CR1 | 12 |
| ≤12 mo from CR1 | 19 |
| Median leucocyte count, ×109/L (range) | 2.92 (0.26‐99.8) |
| Median hemoglobin, g/dL (range) | 9.95 (7.7‐14.5) |
| Median platelet count, ×109/L (range) | 74.5 (5‐407) |
| Median marrow blast percentage (range) | 60 (6‐94) |
| Median duration of follow‐up, mo (range) | 15 (4‐36) |
Abbreviations: CLAM, clofarabine, cytarabine, and mitoxantrone; CR1, first complete remission.
a
Three or more unrelated chromosomal abnormalities in the absence of 1 of the World Health Organization (WHO)‐designated recurring translocations or inversion.